Biogen (BIIB) Earnings Date & Reports

Biogen delivered robust Q1 2026 results. Total revenue hit $2,478 million, a 2% YoY increase that topped the $2.25 billion consensus. Product revenue rose 1% to $1,752 million, with MS products flat at $958 million despite biosimilar pressures on TECFIDERA.

Standouts included growth products at $851 million (up 12% YoY), featuring SKYCLARYS ($151 million, +22%), QALSODY ($33 million, +110%), and Biogen's share of LEQEMBI collaboration revenue ($60 million, +80%). Rare disease revenue dipped 1% to $557 million, impacted by SPINRAZA shipment timing.

GAAP diluted EPS surged 31% YoY to $2.15, while non-GAAP EPS climbed 18% to $3.57, both well above forecasts (non-GAAP consensus $2.95). Guidance for 2026 anticipates mid-single-digit total revenue decline versus 2025, with non-GAAP EPS of $14.25-$15.25, incorporating $1.00 in acquired in-process research and development (IPR&D) charges and excluding Apellis impacts until post-close in Q2.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Biogen's shares rose approximately 2-4% following the April 29 release, trading around $187-$188 in initial reaction. Investors welcomed the earnings beats, robust growth product performance, and Apellis deal progress, though tempered by lowered full-year EPS guidance due to deal-related costs. Sentiment leans positive on pipeline diversification amid MS challenges.

Forward Outlook and Key Factors to Monitor

Investors should track the Apellis acquisition closing in Q2 2026, expected to add SYFOVRE and EMPAVELI with mid- to high-teens revenue growth. Updated guidance post-close will clarify integration impacts, including $120-$130 million in other income/expense from financing.

LEQEMBI ramp-up remains critical, with global in-market sales tripling potential amid expanded label and supply. Growth products like SKYCLARYS and QALSODY offer offsets to MS declines (mid-teens drop ex-VUMERITY expected).

Monitor biosimilars revenue trajectory (low double-digit decline projected) and contract manufacturing (~$600 million, front-loaded). Free cash flow of $594 million in Q1 supports M&A and debt paydown. Overall, execution on cost discipline, tax rate (17-18%), and gross margins will shape EPS delivery versus lowered guidance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations